FDA Advisory Panel Backs Safety, Effectiveness of Optimer's (OPTR) Fidaxomicin in 13-0 Vote
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Join SI Premium – FREE
Optimer (Nasdaq: OPTR) wins the backing of an FDA advisory panel on fidaxomicin. The panel said the drug is safe and effective in a 13-0 vote.
Stock remains halted.
Stock remains halted.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Creative Medical completes enrollment in ADAPT back pain trial
- Hyperfine wins FDA clearance for updated portable MRI software
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
